Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
11860 | 884 | 40.7 | 79% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MINOCYCLINE | Author keyword | 76 | 27% | 28% | 248 |
2 | CHEMICALLY MODIFIED TETRACYCLINES | Author keyword | 24 | 82% | 2% | 14 |
3 | ORAL BIOL PATHOL | Address | 14 | 23% | 6% | 53 |
4 | COL 3 | Author keyword | 12 | 63% | 1% | 12 |
5 | CHEMICALLY MODIFIED TETRACYCLINE | Author keyword | 5 | 60% | 1% | 6 |
6 | CMT 3 | Author keyword | 4 | 67% | 0% | 4 |
7 | DOUBLE MASKED METHOD | Author keyword | 4 | 75% | 0% | 3 |
8 | DOXYCYCLINE THERAPEUTIC USE | Author keyword | 3 | 26% | 1% | 10 |
9 | SUBANTIMICROBIAL DOSE DOXYCYCLINE | Author keyword | 2 | 38% | 1% | 5 |
10 | PERIODONTITIS DRUG THERAPY | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TETRACYCLINES | 22 | 18% | 13% | 111 |
2 | COLLAGENASE ACTIVITY | 19 | 27% | 7% | 62 |
3 | CHEMICALLY MODIFIED TETRACYCLINES | 16 | 36% | 4% | 36 |
4 | COL 3 | 15 | 73% | 1% | 11 |
5 | FLUID COLLAGENASE ACTIVITY | 8 | 75% | 1% | 6 |
6 | 4 DEDIMETHYLAMINO SANCYCLINE | 6 | 80% | 0% | 4 |
7 | REFRACTORY METASTATIC CANCER | 4 | 75% | 0% | 3 |
8 | CHEMICALLY MODIFIED TETRACYCLINE | 3 | 43% | 1% | 6 |
9 | SUBANTIMICROBIAL DOSE DOXYCYCLINE | 3 | 20% | 2% | 15 |
10 | INHIBIT COLLAGENASE | 3 | 100% | 0% | 3 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Minocycline: far beyond an antibiotic | 2013 | 39 | 156 | 52% |
Minocycline and neurodegenerative diseases | 2009 | 171 | 79 | 49% |
Prospects for Minocycline Neuroprotection | 2010 | 78 | 36 | 83% |
What is behind the non-antibiotic properties of minocycline? | 2013 | 15 | 170 | 62% |
Non-anti-infective Effects of Antimicrobials and Their Clinical Applications: A Review | 2015 | 3 | 99 | 21% |
The promise of minocycline in neurology | 2004 | 233 | 55 | 62% |
Tetracyclines: Drugs with Huge Therapeutic Potential | 2012 | 28 | 55 | 44% |
Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study | 2012 | 32 | 32 | 34% |
Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature | 2010 | 73 | 87 | 34% |
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study | 2008 | 59 | 19 | 47% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ORAL BIOL PATHOL | 14 | 23% | 6.0% | 53 |
2 | DENT MED ORAL BIOL PATHOL | 2 | 50% | 0.3% | 3 |
3 | ARTHRIT MUSCULOSKELETAL DIS | 1 | 50% | 0.2% | 2 |
4 | LONGITUDINAL RADIOG ASSESSMENT IL | 1 | 50% | 0.2% | 2 |
5 | PERIODONTAL DIS CLIN | 1 | 33% | 0.3% | 3 |
6 | UNIDAD PFIZER CASTILLA LA MANCHA NEUROPSICOFARMAC | 1 | 40% | 0.2% | 2 |
7 | AIDS MALIGNANCY CONSORTIUM OPERAT | 1 | 33% | 0.2% | 2 |
8 | BEER SHEVA MENTAL HLTH ANXIETY ST S U | 1 | 50% | 0.1% | 1 |
9 | BERLIN STROKE | 1 | 50% | 0.1% | 1 |
10 | CENT HOSP INTERNAL MED 4 | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000168424 | BLACK THYROID//BLACK HAIRY TONGUE//CHRYSIASIS |
2 | 0.0000128007 | GINGIVAL CREVICULAR FLUID//PERI IMPLANT SULCUS FLUID//CREVICULAR FLUID |
3 | 0.0000095203 | PERIODONTITIS DRUG THERAPY//ROOT PLANING//PERIODONTITIS THERAPY |
4 | 0.0000093024 | MODIFIED TETRACYCLINE//IMPERIAL WELLCOME TRUST CLIN TROP MED//MAZANKOWSKI ALBERTA HEART PHARMACOL |
5 | 0.0000065507 | SB 3CT//HEAD SHAKE RESPONSE//BBB BREAKDOWN |
6 | 0.0000065271 | PERIODONTAL DISEASE ETIOLOGY//FRONTIER BIOMED SCI//INFLAMMATORY PERIODONTITIS |
7 | 0.0000064906 | LONG ACTING OXYTETRACYCLINE//LOCAL TOLERANCE//CAS 24390 14 5 |
8 | 0.0000054889 | NEUROPHARMACOL SECT//NEUROANAT EXPT NEUROL//PHARMACOL CHEM |
9 | 0.0000045667 | TUMOR TISSUE PROGRESSION//FIBROBLAST COLLAGENASE//CARRAGEENAN GRANULOMA |
10 | 0.0000043342 | PRURIGO PIGMENTOSA//CONFLUENT AND RETICULATED PAPILLOMATOSIS//TERRA FIRMA FORME DERMATOSIS |